Brind.
  1. Incyte presented research data at the American Society of Hematology Annual Meeting.

CRH Presents Early Trial Results for Nadunolimab at ASH Meeting

2 reports, 1 independent Updated Wed 00:00
No new developments lately Reached 2 outlets in its first 24 hours
Reports
2
Developments
1
Repetition
50%

New informationRepeats or wire copies

AI-generated briefing. Brind wrote this from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

CRH announced early results from a Phase 1b/2a trial of nadunolimab at the American Society of Hematology Annual Meeting. The investigator-initiated trial showed a 70% response rate in 7 of 10 evaluable patients with higher-risk myelodysplastic syndromes treated with nadunolimab and azacitidine. For adverse-risk relapsed or refractory acute myeloid leukemia, the response rate was 33% in 3 of 9 evaluable patients treated with nadunolimab, azacitidine, and venetoclax.

From pr-inside.com

Why it matters

Some supportBrind's analysis of the reports

The results support the view that IL1RAP is a relevant target in hematologic cancers. The Phase 2a expansion of the trial is currently enrolling, with longer-term follow-up data scheduled for an oral presentation at the meeting in December 2026.

From pr-inside.com

Who's involved

  • CRHCompany that presented the early trial results for nadunolimab

Keep exploring

Part of

Incyte presented research data at the American Society of Hematology Annual Meeting. All 1 developments

The entities involved

Coverage

Newest first; wire copies grouped
1 more outlet ran the same wire story